We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

This study has been withdrawn prior to enrollment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01926002
First Posted: August 20, 2013
Last Update Posted: July 16, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
  Purpose
The primary hypothesis of the study is single doses of MK-8351 will reduce the baseline early asthmatic response (EAR) as assessed by area under the curve from 0-3 hours (AUC0-3hr) of forced expiratory volume (FEV1) when compared to placebo.

Condition Intervention Phase
Asthma Drug: Low-Dose MK-8351 Drug: High-Dose MK-8351 Drug: Placebo to MK-8351 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter Randomized Clinical Trial to Study the Effects of Single Doses of MK-8351 on the Early Asthmatic Response to a Lung Allergen Challenge

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • AUC0-3hr of FEV1 Percent Change From Baseline [ Time Frame: 3 Hours ]
  • Number of Participants Experiencing Adverse Events (AEs) [ Time Frame: Up to 14 Days ]
  • Number of Participants Discontinuing Study Treatment Due to AEs [ Time Frame: Up to 72 Hours ]

Secondary Outcome Measures:
  • AUC0-24h of MK-8351 [ Time Frame: Up to 24 Hours Post-Dose ]
  • AUC0-last of MK-8351 [ Time Frame: Up to 72 Hours Post-Dose ]
  • AUC0-∞ of MK-8351 [ Time Frame: Up to 72 Hours Post-Dose ]
  • Maximum Plasma Concentration (Cmax) of MK-8351 [ Time Frame: Up to 72 Hours Post-Dose ]
  • Time to Maximum Plasma Concentration (Tmax) of MK-8351 [ Time Frame: Up to 72 Hours Post-Dose ]
  • Apparent Half-Life (t1/2) of MK-8351 [ Time Frame: Up to 72 Hours Post-Dose ]

Enrollment: 0
Study Start Date: September 2013
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low-Dose MK-8351
Low-dose MK-8351 administered as single inhaled dose.
Drug: Low-Dose MK-8351
Single administration of low-dose MK-8351.
Experimental: High-Dose MK-8351
High-dose MK-8351 administered as a single inhaled dose.
Drug: High-Dose MK-8351
High-Dose MK-8351 administered as a single inhaled dose.
Placebo Comparator: Placebo to MK-8351
Matching placebo to low-dose or high-dose MK-8351 administered as a single inhaled dose.
Drug: Placebo to MK-8351
Single-Dose Matching placebo to high-dose or low-dose MK-8351.

Detailed Description:
This is a randomized, placebo-controlled, 4-period study. Eligible patients will undergo a single-blind phase in Period 1, followed by 3 periods during which they will receive low-dose MK-8351, high-dose MK-8351, or matching placebo as a single dose in a random sequence crossover study design.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Females of non-childbearing potential (at least 1 year post-menopausal, post-hysterectomy, post-oophorectomy, or with tubal ligation);
  • Males with a female partner of childbearing potential must agree to use a medically acceptable method of contraception during and up to 120 days after the last dose of study medication;
  • Body Mass Index (BMI) >=17 kg/m^2 and <=33 kg/m^2
  • Non-smoker and non-user of nicotine or nicotine-containing products for at least 6 months prior to enrollment;
  • History of allergen-induced asthma for at least 6 months prior to enrollment;
  • Able to perform reproducible pulmonary function testing;
  • Positive methacholine challenge test prior to receiving study medication;
  • Allergic response to house dust mite allergen or standardized cat pelt or hair allergen extract;
  • Ability to tolerate sputum induction and to produce adequate sputum.

Exclusion Criteria:

  • History of clinically significant disease or disorder;
  • History of malignancy;
  • History of significant multiple and/or severe allergies;
  • History of milk or lactose allergies or intolerance;
  • History of anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food;
  • Positive for human immunodeficiency virus (HIV), hepatitis B surface antigen, or hepatitis C antibodies;
  • History of major surgery within 3 months prior to enrollment;
  • Participation in another investigational trial within 4 weeks of screening;
  • Lactating females;
  • Inability to refrain from, or anticipates the use of, any medication including herbal remedies during the trial period;
  • History of receiving anti-immunoglobulin E (IgE) or immunotherapy;
  • History of serious allergies to drug or a history of hypersensitivity to inhaled salbutamol, antihistamines, or any other potential asthma/anaphylaxis rescue medication;
  • History of hospitalization for asthma-related illness within 3 months of screening;
  • History of emergent care more than twice in the last 12 months for asthma-related illness;
  • History of life-threatening asthma;
  • Consumes >4 glasses of alcoholic beverage per day;
  • Consumes >6 servings of coffee, tea, cola, energy drinks or other caffeinated beverages per day;
  • History or or current use of illicit drugs within past 24 months.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01926002     History of Changes
Other Study ID Numbers: 8351-003
MK-8351-003 ( Other Identifier: Merck Study Number )
First Submitted: August 16, 2013
First Posted: August 20, 2013
Last Update Posted: July 16, 2015
Last Verified: July 2015